Literature DB >> 25827781

Atorvastatin Prevents Cognitive Deficits Induced by Intracerebroventricular Amyloid-β1-40 Administration in Mice: Involvement of Glutamatergic and Antioxidant Systems.

Wagner C Martins1, Vanessa Valgas dos Santos, Alessandra Antunes dos Santos, Samuel Vandresen-Filho, Tharine A Dal-Cim, Karen A de Oliveira, Claudia B N Mendes-de-Aguiar, Marcelo Farina, Rui Daniel Prediger, Giordano Gubert Viola, Carla I Tasca.   

Abstract

Deposition of amyloid-β (Aβ) peptides into specific encephalic structures has been pointed as an important event related to Alzheimer's disease pathogenesis and associated with activation of glial cells, neuroinflammation, oxidative responses, and cognitive deficits. Aβ-induced pro-oxidative damage may regulate the activity of glutamate transporters, leading to reduced glutamate uptake and, as a consequence, excitotoxic events. Herein, we evaluated the effects of the pretreatment of atorvastatin, a HMG-CoA reductase inhibitor, on behavioral and biochemical alterations induced by a single intracerebroventricular (i.c.v.) injection of aggregated Aβ1-40 in mice. Atorvastatin (10 mg/kg/day, p.o.) was administered through seven consecutive days before Aβ1-40 administration. Aβ1-40 caused significant cognitive impairment in the object-place recognition task (2 weeks after the i.c.v. injection) and this phenomenon was abolished by atorvastatin pretreatment. Ex vivo evaluation of glutamate uptake into hippocampal and cerebral cortices slices showed atorvastatin, and Aβ1-40 decreased hippocampal and cortical Na(+)-dependent glutamate uptake. However, Aβ1-40 increased Na(+)-independent glutamate uptake and it was prevented by atorvastatin in prefrontal cortex slices. Moreover, Aβ1-40 treatment significantly increased the cerebrocortical activities of glutathione reductase and glutathione peroxidase and these events were blunted by atorvastatin pretreatment. Reduced or oxidized glutathione levels were not altered by Aβ1-40 and/or atorvastatin treatment. These results extend the notion of the protective action of atorvastatin against neuronal toxicity induced by Aβ1-40 demonstrating that a pretreatment with atorvastatin prevents the spatial learning and memory deficits induced by Aβ in rodents and promotes changes in glutamatergic and antioxidant systems mainly in prefrontal cortex.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25827781     DOI: 10.1007/s12640-015-9527-y

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  49 in total

1.  The selective and competitive N-methyl-D-aspartate receptor antagonist, (-)-6-phosphonomethyl-deca-hydroisoquinoline-3-carboxylic acid, prevents synaptic toxicity induced by amyloid-β in mice.

Authors:  M A Bicca; C P Figueiredo; T C Piermartiri; F C Meotti; Z L Bouzon; C I Tasca; R Medeiros; J B Calixto
Journal:  Neuroscience       Date:  2011-07-01       Impact factor: 3.590

Review 2.  Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress.

Authors:  D Allan Butterfield; Christopher M Lauderback
Journal:  Free Radic Biol Med       Date:  2002-06-01       Impact factor: 7.376

3.  Hydrogen peroxide is generated during the very early stages of aggregation of the amyloid peptides implicated in Alzheimer disease and familial British dementia.

Authors:  Brian J Tabner; Omar M A El-Agnaf; Stuart Turnbull; Matthew J German; Katerina E Paleologou; Yoshihito Hayashi; Leanne J Cooper; Nigel J Fullwood; David Allsop
Journal:  J Biol Chem       Date:  2005-09-01       Impact factor: 5.157

4.  Selective loss of central cholinergic neurons in Alzheimer's disease.

Authors:  P Davies; A J Maloney
Journal:  Lancet       Date:  1976-12-25       Impact factor: 79.321

5.  Necropsy evidence of central cholinergic deficits in senile dementia.

Authors:  E K Perry; R H Perry; G Blessed; B E Tomlinson
Journal:  Lancet       Date:  1977-01-22       Impact factor: 79.321

Review 6.  Safety of high-dose atorvastatin therapy.

Authors:  David D Waters
Journal:  Am J Cardiol       Date:  2005-09-05       Impact factor: 2.778

7.  Statins and the risk of dementia.

Authors:  H Jick; G L Zornberg; S S Jick; S Seshadri; D A Drachman
Journal:  Lancet       Date:  2000-11-11       Impact factor: 79.321

8.  Neuronal glutathione deficiency and age-dependent neurodegeneration in the EAAC1 deficient mouse.

Authors:  Koji Aoyama; Sang Won Suh; Aaron M Hamby; Jialing Liu; Wai Yee Chan; Yongmei Chen; Raymond A Swanson
Journal:  Nat Neurosci       Date:  2005-11-27       Impact factor: 24.884

9.  Beta-amyloid (1-42)-induced learning and memory deficits in mice: involvement of oxidative burdens in the hippocampus and cerebral cortex.

Authors:  Jin Hyeong Jhoo; Hyoung-Chun Kim; Toshitaka Nabeshima; Kiyofumi Yamada; Eun-Joo Shin; Wang-Kee Jhoo; Wookyung Kim; Kee-Seok Kang; Sangmee Ahn Jo; Jong Inn Woo
Journal:  Behav Brain Res       Date:  2004-12-06       Impact factor: 3.332

10.  Alkaline hydrolysis of N-ethylmaleimide allows a rapid assay of glutathione disulfide in biological samples.

Authors:  P Sacchetta; D Di Cola; G Federici
Journal:  Anal Biochem       Date:  1986-04       Impact factor: 3.365

View more
  9 in total

1.  Atorvastatin and Fluoxetine Prevent Oxidative Stress and Mitochondrial Dysfunction Evoked by Glutamate Toxicity in Hippocampal Slices.

Authors:  Fabiana K Ludka; Tharine Dal-Cim; Luisa Bandeira Binder; Leandra Celso Constantino; Caio Massari; Carla I Tasca
Journal:  Mol Neurobiol       Date:  2016-04-06       Impact factor: 5.590

2.  Mevastatin promotes neuronal survival against Aβ-induced neurotoxicity through AMPK activation.

Authors:  Edy Kornelius; Hsin-Hua Li; Chiung-Huei Peng; Hui-Wen Hsiao; Yi-Sun Yang; Chien-Ning Huang; Chih-Li Lin
Journal:  Metab Brain Dis       Date:  2017-08-24       Impact factor: 3.584

3.  Atorvastatin Prevents Early Oxidative Events and Modulates Inflammatory Mediators in the Striatum Following Intranasal 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Administration in Rats.

Authors:  Naiani F Marques; Adalberto A Castro; Gianni Mancini; Fernanda L Rocha; Adair R S Santos; Rui D Prediger; Andreza Fabro De Bem; Carla I Tasca
Journal:  Neurotox Res       Date:  2017-11-21       Impact factor: 3.911

4.  Atorvastatin Protects from Aβ1-40-Induced Cell Damage and Depressive-Like Behavior via ProBDNF Cleavage.

Authors:  Fabiana K Ludka; Maurício P Cunha; Tharine Dal-Cim; Luisa Bandeira Binder; Leandra C Constantino; Caio M Massari; Wagner C Martins; Ana Lúcia S Rodrigues; Carla I Tasca
Journal:  Mol Neurobiol       Date:  2016-10-05       Impact factor: 5.590

5.  Atorvastatin Prevents Glutamate Uptake Reduction Induced by Quinolinic Acid Via MAPKs Signaling.

Authors:  S Vandresen-Filho; W C Martins; D B Bertoldo; D K Rieger; M Maestri; R B Leal; C I Tasca
Journal:  Neurochem Res       Date:  2016-04-15       Impact factor: 3.996

6.  Guanosine Prevents Anhedonic-Like Behavior and Impairment in Hippocampal Glutamate Transport Following Amyloid-β1-40 Administration in Mice.

Authors:  Débora Lanznaster; Josiel M Mack; Victor Coelho; Marcelo Ganzella; Roberto F Almeida; Tharine Dal-Cim; Gisele Hansel; Eduardo R Zimmer; Diogo O Souza; Rui D Prediger; Carla I Tasca
Journal:  Mol Neurobiol       Date:  2016-09-06       Impact factor: 5.590

7.  Role of inflammatory, oxidative, and ER stress signaling in the neuroprotective effect of atorvastatin against doxorubicin-induced cognitive impairment in rats.

Authors:  Noha M Mounier; Sara A Wahdan; Amany M Gad; Samar S Azab
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-03-23       Impact factor: 3.000

8.  Atorvastatin-mediated rescue of cancer-related cognitive changes in combined anticancer therapies.

Authors:  Junho Lee; Jin Su Kim; Yangjin Kim
Journal:  PLoS Comput Biol       Date:  2021-10-20       Impact factor: 4.475

Review 9.  Neuroprotective effects of statins against amyloid β-induced neurotoxicity.

Authors:  Hsin-Hua Li; Chih-Li Lin; Chien-Ning Huang
Journal:  Neural Regen Res       Date:  2018-02       Impact factor: 5.135

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.